

Curriculum Vitae

Name:	Johan H. Jendle
Academic Title:	MD, PhD, Professor
Born:	Gothenburg, Sweden, 14th of May 1963
Citizenship:	Swedish
Civil status:	Married to Cecilia Jendle (MD), four children: Hampus 29 yrs, Carl 26 yrs, Theodor 22 yrs and Filippa 15 yrs
Academic Degree:	Medical Degree at Linköping University, Sweden, January 1991 Medical Thesis (Dr Med Sci), Linköping University, Sweden, December 1996 Associate professor, School of Health and Medical Sciences, Örebro University, Sweden, 2010-2015 Professor, School of Medical Sciences, Örebro University, Sweden 2015-
Education:	Internship at the Hospital of Karlstad, Sweden, 1991-1992 Consultant in Submarine Medicine, Swedish Royal Navy, 1992-2010 Research fellow at the University Hospital of Linköping, Sweden, 1993-1996 Residency, Internal Medicine, Endocrinology and Diabetes, Linköping University Hospital, 1993-1998 Specialist in Endocrinology and Diabetes 1998 Specialist in Internal Medicine 2001 Specialist in Internal Medicine and Endocrinology in Norway 2002 Certified Diving Physician (EDTC/ECHM approved) 2009
Affiliations:	Member of the Swedish Society of Medicine 1996- Member of the Swedish Society of Endocrinology 1996- Member of the American Diabetes Association (ADA) 1998- Member of the European Association for the study of Diabetes (EASD) 2002- Member of the Swedish Society for Diabetology 2005-
Appointments:	Clinical tutor at the School of Medicine, Linköping University, 1993-1997 Physician in Submarine-Medicine for the Swedish Royal Navy, 1992-2010 Lieutenant in the Swedish Royal Navy, 1993-2010 International Clinical Project Manager, Novo Nordisk A/S, Clinical Drug Development, 1999-2001 Member of the formulatory committee in the region of Skåne, 2001-2004 Consultant in Endocrinology, Diabetes and Internal Medicine, Trelleborg Hospital, 2001-2004 Head of dept of Internal Medicine, Trelleborg Hospital, 2001-2004 Consultant dept of Endocrinology Malmö University Hospital, 2003- 2004 Consultant, Endocrine and Diabetes Centre, Karlstad Hospital, 2004-2016 Member of the Board of Clinical Research, Värmland, 2005-2016 Board member of the Swedish Society for Diabetology, 2006-2017 Secretary of the Swedish Society for Diabetology, 2007-2009 Scientific Secretary of the Swedish Society for Diabetology, 2014-2017 Scientific Leader, Clinical Research Centre, Värmland, 2007-2016 Member of the Diabetes expert group of the National board of health and welfare, 2007-2009 Chairperson, expert group diabetes, formulatory committee in the region of Värmland, 2008-2016 Visiting Teacher, Faculty of Health Sciences, Örebro University Hospital, 2007-2009 Board member, Regional Research Council, Örebro-Uppsala, 2010-2016 Member of the National Program Council, Diabetes, 2012-2014 Director of the Endocrine and Diabetes Center, Karlstad Hospital, Sweden 2014-2016 Senior consultant in Endocrinology, Örebro University Hospital, Sweden 2017- Committee Member, Medscape, 2014-2018 Member of the eye complication study group EASDec, 2016- Member of the physical activity study group EASD (Expas), 2016- Committee Member, JDRF physical activity and diabetes, 2016- Member of the Swedish National Board for Internship Examination, 2016- Board member of the Professor Council of the Vice Chancellor, Örebro University, 2017- Director of the Diabetes, Endocrinology and Metabolism Research Center, Örebro University, 2017- Deputy head of Department of Medical Sciences, Örebro University, 2018-2019 Specialization coordinator, Örebro University, 2018-2020 Faculty board member, Örebro University, 2019-2020 Chair Academic Appointments Committee, Örebro University, 2019- Board member Research Assessment Committee, ORU2020, Örebro University, 2019-2020 Board member Research Council, department of Medical Sciences, Örebro University, 2020- Board member of The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) working group on continuous glucose monitoring (CGM), 2020- Elector for the Swedish Research Council, 2021- Advisory Board GSK, 2007-2009 Advisory Board Pfizer, 2008-2012 Advisory Board Janssen, international level, 2013-2015 Advisory Board Roche Diagnostics, international level, 2013-2017 Advisory Board Boehringer Ingelheim, international level, 2010- Advisory Board AstraZeneca, national level, 2015- Advisory Board Medtronic Inc., international level, 2010- Advisory Board Eli Lilly, international level, 2011- Advisory Board Novo Nordisk, international level, 2011- Advisory Board Abbott, international level, 2013-2015, 2019- Reviewer, Diabetes Obesity and Metabolism, 2010- Reviewer, Journal of Diabetes Science and Technology, 2012- Reviewer, Journal of Diabetes Technology and Therapeutics, 2013-

	<p>Reviewer, Diabetologia, 2014- Reviewer Lancet, 2017- Reviewer Drugs, 2019- Editorial Board, Frontiers in Endocrinology, 2012- Guest editor Frontiers in Endocrinology, 2018-2019 Editorial board, MedCom, 2015-2019 Co-editor, Journal of Diabetes Science and Technology, 2015- Co-Supervisor, PhD student Payam Khalili MD, Örebro University 2007-2012 Supervisor, PhD student Peter Adolfsson MD, Sahlgrenska Academy, Gothenburg Univ, 2006-2012 Supervisor, PhD student Stig Mattsson, Örebro University, 2013- Supervisor, PhD Student Marije Galavazi, Örebro University, 2018- Supervisor, PhD Student Ali Sharif, Örebro University, 2018- Co-Supervisor, PhD Student Qays Shahed, Örebro University, 2020-</p>
Publications:	<p>Papers:</p> <ol style="list-style-type: none"> 1. Jendle J, Nilsson A and Nilsson L. Subpopulations of variants resistant imipenem in pseudomonas aeruginosa. J Antimicrobial Chemotherapy 1988;22:643-649. 2. Jendle J, Karlberg BE, Persliden J, Franzén T, Arborelius M. Delivery and retention of an insulin aerosol produced by a jet nebulizer. J Aerosol Med 1995;8:243-254. 3. Jendle J, Karlberg BE, Arborelius M. An exploration of intrapulmonary insulin administration in anesthetized and mechanically ventilated pigs. Scand J Clin Lab Invest. 1996;56:251-258. 4. Jendle J and Karlberg BE. Intrapulmonary insulin administration to healthy volunteers. J Intern Med. 1996;240:93-98. 5. Jendle J and Karlberg BE. Effects of intrapulmonary insulin administration in patients with non-insulin-dependent diabetes. Scand J Clin Lab Invest 1996;56:555-561. 6. Brunner, Balent, Ellmerer, Schaupp, Sibbenhofer, Jendle J, Okikawa J, Pieber T. Dose-response relationship of liquid aerosol inhaled insulin in Type 1 diabetic patients. Diabetologia. 2001;44:305-308. 7. Lundström, Jendle J, Stenström, Toss G, Ravalid N. Periodontal conditions in 70-year-old women with osteoporosis. Swed Dent J. 2001;25:89-96. 8. Himmelmann, Jendle J, Mellén, Petersen A, Dahl, Wollmer P. The impact of smoking on inhaled insulin. Diabetes Care. 2003;26:677-682. 9. Kölendorf, Ross, Pavlic-Renar, Periello, Philotheou, Jendle J, Gall K, Heller S. Insulin detemir lowers the risk of hypoglycemia and provides more consistent plasma glucose levels compared with NPH insulin in type 1 diabetes. Diabetic Medicine. 2006;23:729-735. 10. Jendle J and Norberg B. Clinical experiences with Levemir treatment. Läkartidningen 2007;104:54. 11. Godall, Jendle, Valentine, Munro, Brandt, Ray, Roze, Foes, Palmer. Biphasic insulin aspart 70/30 versus insulin glargine in insulin naïve type 2 diabetes patients: Modeling the long-term health economic implications in a Swedish setting. Int J Clin Pract. 2008;62:869-876. 12. Adolfsson P, Örnhammar H and Jendle J. The benefits of continuous glucose monitoring and a glucose monitoring schedule in individuals with type 1 diabetes during recreational diving. J Diabetes Sci Technol. 2008;2:778-784. 13. Jendle J. Resource utilization and costs for the treatment of diabetes in the developed world-an economical burden that needs to be solved. Int J Clin Pract 2009;63:980-982. 14. Adolfsson P, Örnhammar H and Jendle J. Accuracy and reliability of Continuous Glucose Monitoring in individuals with Type 1 Diabetes during Recreational Diving. Diabetes Technology and Therapeutics. 2009;8:493-497. 15. Jendle J, Nauck MA, Matthews D, Frid A, Hermansen K, During M, Zdravkovic, M, Strauss BJ, Garber A. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment, is primarily due to a reduction in fat tissue. Diabetes, Obesity & Metabolism 2009;11:1163-1172. 16. Khalili P, Flyvbjerg A, Frystyk, Lundin, Jendle J, Engström and Nilsson P. Total adiponectin does not predict cardiovascular events in middle-aged men in a prospective, long term follow-up study. Diabetes Metab 2010;36:137-43. 17. Jendle J, Torffvit O, Ridderstråle M, Lamert M, Ericsson A, Bøgelund M. Willingness-to-pay for health improvements associated with pharmacological antidiabetic treatments in people with type 2 diabetes. Curr Med Res Opin 2010;26:917-923. 18. Færch M, Corydon, Hertz, Rittig S and Jendle J. Skewed X-chromosome inactivation causing diagnostic misinterpretation in congenital nephrogenic diabetes insipidus. Scandinavian Journal of Urology and Nephrology. Scand J Urol Nephrol. 2010;44:324-330. 19. Birkeland K, Home P, Wendisch U, Ratner R, Johansen T, Endahl L, Lyby K, Jendle J, Roberts A, DeVries J, Meneghini L. Insulin Degludec in type 1 diabetes. Diab Care. 2011;34:661-665. 20. Valentine W, Jendle J, Saraheimo M, Thorsteinsson B, Pollock R, Lammert M. Evaluating the cost-effectiveness of reduced mild hypoglycemia in subjects with type 1 diabetes treated with Insulin detemir or NPH insulin in Denmark, Sweden, Finland and the Netherlands. Diabet Med 2011;28:1-10. 21. Jendle J, Adolfsson P, Atvall S, Örnhammar H. Diving in diabetes possible but not without risks. Läkartidningen. 2011;44:2230-2231. 22. Jendle J, Adolfsson P. The impact of high altitudes on glucose control. J Diabetes Sci Technol. 2011;5:1621-1622. 23. Home PD, Meneghini L, Wendisch U, Ratner RE, Johansen T, Christensen TE, Jendle J, Roberts AP, DeVries J, Birkeland KI. Improved health-related quality of life with insulin degludec compared with insulin glargine in people with type 1 diabetes. Diabetic Medicine. 2012;29:716-720. 24. Lind M, Jendle J, Torffvit O, Lager B. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction. Primary care diabetes 2012;6:41-46. 25. Jendle J, Ridderstråle M, Torffvit O, Ericsson Å, Larsen S. Willingness-to-pay for benefits associated with basal insulin treatment in type 2 diabetes. J Med Econ. 2012;15(2):261-3. doi: 10.3111/13696998.2011.644408 26. Adolfsson P, Örnhammar H, Eriksson BM, Cooper K, Jendle J. Continuous glucose monitoring – a study of the ENLITE sensor during hypo- and hyperbaric conditions. Diabetes Technology and Therapeutics. 2012;14:527-532. 27. Jendle J, Torffvit O, Ridderstråle M, Ericsson Å, Nilsen B, Bøgelund M. Willingness to pay for diabetes drug therapy in type 2 diabetes patients based on LEAD clinical program results. J Med Econ. 2012;15 Suppl 2:1-5. doi: 10.3111/13696998.2012.703633. 28. Khalili P, Sundström J, Franklin S, Jendle J, Lundin F, Jungner I, Nilsson PM. Combined effects of brachial

pulse pressure and serum sialic acid predicting risk for cardiovascular events during 40-years of follow-up in 37,843 subjects: The Värmland Survey, Sweden. *J Hypertension*. 2012;30:1718-1724.

29. Jendle J, Christensen JH, Kvistgaard H and Rittig S. Late onset adult familial neurohypophyseal diabetes insipidus due to a novel mutation in the AVP gene. *Clin Endocrinology*. 2012;77:586-592.

30. Freemantle, Meneghini L, Christensen, Wolden, Jendle J, Ratner RE. Insulin degludec improves health related quality of life (SF-36) compared with insulin glargine in people with type 2 diabetes. *Diab Medicine* 2012;29:716-720.

31. Adolfsson P, Örnhagen H, Eriksson BM, Gautham R, Jendle J. The in-vitro performance of the Enlite sensor in various glucose concentrations during hypobaric and hyperbaric conditions. *Diabetes Sci and Technol*. 2012;14527-532.

32. Jendle J, Adolfsson P, Örnhagen H. Swedish recommendations on recreational diving and diabetes mellitus. *Diving and Hyperbaric Medicine*. 2012;42:231-233.

33. Jendle J, Martin SA, Milicevic Z. Insulin and GLP-1 analog combination: A Critical Review. *Expert Opin Investig Drugs*. 2012 :21;1463-74.

34. Jendle J, Alvarsson M, Hanås R, Attvall S. Mätning av blodketoner, när, var, hur. *Läkartidningen*. 2012;109:2031-2032.

35. Freemantle N, Meneghini L, Christensen TE, ML Wolden, Jendle J, Ratner RE. Insulin degludec improves health-related Quality of Life (SF-36) compared with insulin glargine in people with type 2 diabetes: a meta-analysis of phase 3a trials using basal oral therapy. *Diabet. Med*. 2013;30:226-232.

36. Yousef M, Westman A, Lindberg A, de Lacerda C, Jendle J. Glucose Changes and working memory in individuals with type 1 diabetes during air pressure changes simulating skydiving. *Diabetes Technol Ther*. 2014;16:56-62.

37. Khalili P, Sundström J, Jendle J, Lundin F, Jungner I, Nilsson PM. Sialic acid and incidence of hospitalization for diabetes and its complications during 40-years of follow-up in a large cohort: The Värmland Survey. *Primary Care Diabetes* 2014;8:352-357.

38. Roze S, Brandt A-S, De Portu S, Papo N, Jendle J. Health-Economic analysis of real-time continuous glucose monitoring in people with type 1 Diabetes. *Diabetic Medicine*. 2015;32:618-626.

39. Blonde L, Jendle J, Gross J, Woo V, Jiang H, Fahrbach JL, Milicevic Z. Once weekly dulaglutide versus bedtime insulin glargine both in combination with prandial insulin lispro in patients with type 2 diabetes (AWARD-4): a randomised, open-label phase 3, non-inferiority study. *The Lancet*. 2015;385:2057-2066.

40. Steineck I, Cederholm J, Eliasson B, Rawshani A Eeg-Olofsson K, Svensson AM, Zethelius B, Avdic T, Landin-Olsson M, Jendle J, Gudbjörnsdóttir S; Swedish National Diabetes Register. Insulin pump therapy, multiple daily injections, and cardiovascular mortality in 18,168 people with type 1 diabetes: observational study. *BMJ*. 2015 DOI:10.1136/bmj.h3234

41. Adolfsson P, Mattsson S, Jendle J. Evaluation of glucose control when a new strategy of increased carbohydrate supply is implemented during prolonged physical exercise in type 1 diabetes. *Europ J Appl Physiol*. 2015;12:2599-2607.

42. Adolfsson P, Strömgren A, Mattsson S, Chaplin J, Jendle J. Education and individualized support regarding exercise and diabetes improves glucose control and level of physical activity in type 1 diabetes individuals. *J Endocrine Diabetes & Obesity*. 2015;3(2):1071-1077.

43. Ridderstråle M, Evans LM, Jensen HH, Bøgelund M, Jensen MM, Ericsson A, Jendle J. Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study. *Health Qual Life Outcomes*. 2016 22;14:13. DOI:10.1186/s12955-016-0411-0.

44. Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT. Efficacy and Safety of Dulaglutide in the Treatment of Type 2 Diabetes; A Comprehensive Review of the Dulaglutide Clinical data focusing on the AWARD Phase 3 Clinical Trial Program. *Diabetes Metab Res Rev*. 2016;32(8):776-790.

45. Jendle J, Testa M, Martin S, Jiang H, Milicevic Z. Continuous Glucose Monitoring in Type 2 Diabetes Patients Treated with GLP-1 Receptor Agonist Dulaglutide in Combination with Prandial Insulin Lispro - An AWARD-4 Substudy. *Diabetes Obes Metab*. 2016;18(10):999-1005.

46. Jendle J, Rawshani A, Svensson A-M, Avdic T, Gudbjörnsdóttir S. Indications for insulin pump therapy in type 1 diabetes and associations with glycemetic control. *J Diabetes Sci Technol*. 2016;10(5):1027-1033.

47. Jendle J, Rinnert K, Westman A, Heinemann L. Pilots and Diabetes Technology: Functional Health. *JDST*, 2017;11:191-194.

48. Mattsson S, Adolfsson P, Jendle J. Sports camps for adults with type 1 diabetes associated with improved self-estimated knowledge and glycemetic control. *J Dia Res Ther* 2017 3(1): doi.org/10.16966/2380-5544.127

49. Jendle J, Smith-Palmer J, Delbaere A, de Portu S, Papo N, Valentine W, Roze S. Cost-effectiveness analysis of sensor augmented insulin pump therapy versus standard insulin pump therapy in patients with type 1 diabetes in Sweden. *Diabetes Ther*. 2017. DOI:10.1007/s13300-017-0294-z

50. Jendle J, Ericsson A, Hunt B, Valentine WJ, Pollock RF. Achieving good glycemetic control early after onset of diabetes is cost effective for patients with type 1 diabetes in Sweden. *Diabetes Ther*. 2017. doi.org/10.1007/s13300-017-0344-6.

51. Nyström T, Santos-Pardo I, Hedberg F, Wardell J, Witt N, Yang C, Bojö L, Nilsson B, Jendle J. Effects on subclinical heart failure in type 2 diabetic subjects on liraglutide treatment vs. glimepiride both in combination with metformin. *Frontiers Endocrinology*. 2017;8:325. DOI:10.3389/fendo.2017.00325.

52. Jendle J, Fang X, Cao Y, Bojö L, Nilsson BK, Hedberg F, Santos-Pardo I, Nyström T. Effects on repetitive 24-hour ambulatory blood pressure in type 2 diabetic subjects randomized to liraglutide or glimepiride treatment both in combination with metformin: A randomized open parallel-group study. *J Am Soc Hypertens*. 2018;12:346-355.

53. Jendle J, Sandberg A, Buchs S, Swinburn P, Hadi M, Levin L-Å. A utility valuation study assessing the impact of postprandial glucose control on quality of life of individuals with type 1 or type 2 diabetes. *Journal of Patient-Reported Outcomes*. 2018: 2:20. doi.org/10.1186/s41687-018-0045-6

54. Jendle J and Heinemann L. Real-time Continuous Glucose Monitoring Usage in Pilots with Diabetes: An Option to Improve Safety. *DTT*. 2018;20:453-454.

55. Nyström T, Santos-Pardo I, Hedberg F, Fang X, Cao Y, Bojö L, Nilsson BK, Jendle J. Heart rate variability in type 2 diabetic subjects randomized to liraglutide or glimepiride treatment both in combination with metformin: A randomized open parallel-group study. *Endocrinology, Diabetes & Metabolism*. 2019. DOI:10.1002/edm2.58

56. Jendle J, Pöhlmann J, de Portu S, Smith-Palmer J, Roze S. Cost-effectiveness analysis of the MiniMed™ 670 G hybrid closed loop system versus subcutaneous insulin infusion for treatment of type 1 diabetes. *DTT*. 2019;21:110-118. DOI:10.1089/dia.20180328.

57. Jendle J, Birkenfeld AL, Polonsky WH, Silver R, Uusinarkaus K, Hansen T, Håkan-Bloch J, Tadayon S, Davies M. Improved treatment satisfaction in people with type 2 diabetes treated with once-weekly semaglutide in the SUSTAIN trials. *DOM*. 2019. DOI:10.1111/dom.13816
58. Fadini GP, Feher M, Hansen TK, de Valk HW, Koefoed MM, Wolden M, Zimmermann E, Jendle J. Reduced rates of any hypoglycaemia in patients with type 1 or type 2 diabetes after switching to insulin degludec from other basal insulins: a multi-national, multi-centre, prospective, observational study (ReFLect). *JCEM*. 2019;104(12):5977–5990. doi.org/10.1210/jc.2019-01021
59. Mattsson S, Jendle J, Adolfsson P. Carbohydrate loading before and intermittent high carbohydrate intake during prolonged physical exercise in individuals with type 1 diabetes is associated with good glucose control. *Frontiers of Endocrinology*. 2019. DOI:10.3389/fendo.2019.00571
60. Jendle J and Riddell M. Editorial: Physical Activity and Diabetes. *Frontiers of Endocrinology*. 2019. DOI:10.3389/fendo.2019.00860
61. Jendle J, Adolfsson P. Continuous glucose monitoring diving and diabetes: an update of the Swedish recommendations. *JDST* 2020;14(1):170–173. DOI:10.1177/1932296819826584
62. Jendle J, Peter Adolfsson P, Neal Pollock. Diving with type 1 and type 2 diabetes – advancing capabilities and recommendations. *DHM*. 2020;50(2):135-143. DOI:10.28920/dhm50.2.135-143.
63. Jendle J. The use of e-health for the care of patients with diabetes in connection to the COVID-19 pandemic. *JDST*. 2020. DOI:10.1177/93229680922623
64. Persson S, Johansen P, Andersson E, Lindgren P, Thielke D, Thorsted BL, Jendle J & Steen Carlsson K. Days absent from work due to complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden. *DOM*. 2020. doi.org/10.1111/dom.14070
65. Jendle J, Landin B, Jansson S, Nordin G. När HbA1c inte stämmer-Vissa individer kan få vilseledande resultat. *Läkartidningen*. 2020;117:20001.
66. de Valk HW, Feher M, Krarup Hansen T, Jendle J, Merchante A, Koefoed MM, Rizi EH, Zimmermann E, Fadini GP. Switching to Degludec is Associated with Reduced Hypoglycaemia, Irrespective of Definition Used or Patient Characteristics: Secondary Analysis of the ReFLect Prospective, Observational Study. *Diab Ther*. 2020. https://doi.org/10.1007/s13300-020-00875-1
67. Jendle J, Ericsson Å, Ekman B, Sjöberg S, Gundgaard J, da Rocha Fernandes J, Mårdby AC, Hunt B, Malkin SJP, Thunander M. Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective. *Journal of Medical Economics*. 2020. doi.org/10.1080/13696998.2020.1805454
68. Andersson E, Persson S, Hallén N, Ericsson Å, Thielke D, Lindgren P, Steen Carlsson K, Jendle J. Costs of diabetes complications: Hospital based care and production loss for 392,200 people with type 2 diabetes and matched controls in Sweden. *Diabetologia*. 2020. Doi 10.1007/s00125-020-05277-3
69. Groop PH, Dandona P, Phillip M, Gillard P, Edelman S, Jendle J, Xu J, Scheerer MF, Thoren F, Iqbal N, Repetto N, Mathieu C. Effect of dapagliflozin as an adjunct to insulin on urinary albumin-to-creatinine ratio over 52 weeks in adults with type 1 diabetes. *Lancet Endocrinology*. 2020. doi.org/10.1016/S2213-8587(20)30280-1.
70. Sharif A, Jendle J, Hellgren K-J. Screening for diabetic retinopathy with extended intervals: A retrospective cohort study. *Diabetes Ther*. 2020. https://doi.org/10.1007/s13300-020-00957-0
71. Huhn E, Eppel D, Weißhaupt K, X Klapp C, Schellong K, Yerlikaya-Schatten G, Rosicky I, Husslein P, Chalubinski K, Mittlböck M, Rust P, Hösl I, Donath M, Winzeler B, Jendle J, Fehm F, Icks A, Vomhof M, Montalbo J, Szendrödi J, Roden M, Tura A, Göbl C. The Effectiveness of Real-Time Continuous Glucose Monitoring to Improve Glycaemic Control and Pregnancy Outcome in Patients with Gestational Diabetes Mellitus. *BMJ Open*. 2020;10(11):e040498. DOI: 10.1136/bmjopen-2020-040498
72. Jendle J, Ericsson Å, Gundgaard J, Bech Møller J, Valentine WJ, Hunt B. Smart Insulin Pens are Associated with Improved Clinical Outcomes at Lower Cost Versus Standard-of-Care Treatment of Type 1 Diabetes in Sweden: A Cost-Effectiveness Analysis. *Diabetes Therapy*. 2021;12(1):373-388. DOI 10.1007/s13300-020-00980-1
73. Jendle J, Jansson S. Kontinuerlig glukosmätning (CGM) vid typ 2-diabetes. *Läkartidningen*. 2021;118:20158.
74. Karlsson J, Galavazi M, Jansson S, Jendle J. Effects on body weight, eating behavior and quality of life of a low energy diet combined with behavioral group treatment of persons with class II or III obesity: a 2-year pilot study. *Obesity Science & Practice*. 2021;7:4-13. DOI: 10.1002/osp4.464
75. Jendle J, Ampudia-Blasco F, Fuchtenbusch M, and Pozzilli P. Dapagliflozin as adjunct therapy to insulin in patients with type 1 diabetes mellitus – efficacy and safety of this combination. *touchREVIEWS in Endocrinology*. 2021;17(1):12-20.
76. Isaksson SS, Bensow Bacos M, Eliasson B, Thors-Adolfsson E, Rawshani A, Lindblad U, Jendle J, Berglund A, Lind M, Axelsen M. Effects of nutrition education using food-based approach, carbohydrate counting or regular routine in type 1 diabetes: 12 months prospective randomized trial. 2021. *BMJ open diabetes research and care*. http://dx.doi.org/10.1136/bmjdr-2020-001971
77. Da Silva J, Bosi E, Jendle J, Arrieta A, Castaneda J, Grossman B, Cordero TL, Shin J, Cohen O. Real-world performance of the MiniMed™ 670G system in Europe. *DOM*. 2021;1-8. doi.org/10.1111/dom.14424
78. Mattsson S, Adolfsson P, Jendle J, Bengtsson V, Sparud-Lundin C. Empowered by intertwined theory and practice – experiences from a diabetes sports camp for physically active adults with type 1 diabetes. *Clinical Diabetes Frontiers*. 2021. doi: 10.3389/fcdc.2021.655238
79. Jendle J, Hyötyläinen T, Oresic M, Nyström T. Pharmacometabolomic profiles in type 2 diabetic subjects treated with Liraglutide or Glimepiride. In manuscript. *Target journal Diabetologia*.
80. Jendle J, Eeg-Olofsson K, Svensson AM, Franzen S, Lamotte M and Levrat-Guillen F. Cost-Effectiveness of the FreeStyle Libre® system versus Blood Glucose Self-Monitoring in People with Type 2 Diabetes on Insulin treatment. In manuscript. *Target journal DOM*.
81. Jendle J, Holm AL, de Porta S, Cohen O, Buompensiere MI, Malkin SJP. The cost-effectiveness of an advanced hybrid closed-loop system in people with type 1 diabetes: A health economic analysis in the Swedish setting. Submitted. *Diat Therapy*.
82. Jendle J, Steen Carlsson K, Persson S, Nilsson K. Resource utilization, complications and mortality in type 2 diabetes subject and matched controls. In manuscript. *Target journal Diabetes Care*.
83. Persson S, Nilsson K, Karlsdotter K, Skogsberg J, Gustavsson S, Jendle J, Steen Carlsson K. Burden of established cardiovascular disease and type 2 diabetes. In manuscript *Burden of established cardiovascular disease in people with type 2 diabetes and matched controls: Hospital-based care, days absent from work, costs, and mortality*. In manuscript *target Diab Care*.
84. Sharif A, Cao Y, Hellgren KJ, Jendle J. Prevalence of type 2 diabetes and diabetic retinopathy amongst elderly. In manuscript. *Target journal NEJM*.

85. Jendle J, Ojesic M, Hytulainen T, Nystrom T. Plasma levels of miR-206 in individuals with type 2 diabetes after treatment with Liraglutide or Glimepiride. In manuscript.

Books/book chapters:

1. Clauson P, Balent, Brunner, Sendlhofer, Jendle J, Hatorp, Dahl, Okikawa J, Pieber T. PK-PD of four different doses of pulmonary insulin delivered with the AERx® Diabetes Management System. In: RN Dalby; PR Byron, SJ Farr, J Perth eds. Resp Drug Delivery VII. Raleigh NC: Serentec Press. 2000. pp 155-161.
2. Insulinkompndiet. Redaktör Anders Toll. Eli Lilly. PP-LD-SE-0442. 2016.
3. Inkretinkompndiet. Inkretinbehandling vid typ 2 diabetes. Redaktörer Bo Åhrén & Anders Toll. Eli Lilly. 2017.
4. FYSS2012. Fysisk aktivitet i sjukdomsprevention och sjukdomsbehandling. Yrkesföreningar för fysisk aktivitet (YFA). Stockholm: Läkartidningen förlag AB. 2011.
5. FYSS2015. Fysisk aktivitet i sjukdomsprevention och sjukdomsbehandling. Yrkesföreningar för fysisk aktivitet (YFA). 2:a rev upplagan. Stockholm: Läkartidningen förlag AB. 2014.
6. FYSS2017 Fysisk aktivitet i sjukdomsprevention och sjukdomsbehandling. Yrkesföreningar för fysisk aktivitet (YFA). 3:e rev upplagan. Stockholm: Läkartidningens förlag AB. 2016. ISBN 9789198171129.
7. Johan Henrik Jendle, Michael Charles Riddell and Timothy William Jones. "Physical Activity and Type 1 Diabetes". Lausanne: Frontiers Media SA. 2020. doi: 10.3389/978-2-88963-423-1. ISSN 1664-8714. ISBN 978-2-88963-423-1.
8. Diabetes. Insulinbehandling, p 107-117. Redaktör M Landin-Olsson. Studentlitteratur AB, Lund. 2020. ISBN 978-91-44-13110-84.
9. FYSS2021 Fysisk aktivitet i sjukdomsprevention och sjukdomsbehandling. Yrkesföreningar för fysisk aktivitet (YFA). 4:e rev upplagan. Stockholm: Läkartidningens förlag AB. 2021.

Abstracts:

1. Jendle J, Karlberg BE. Intrapulmonary administration of insulin to healthy volunteers. OP EASD1995.
2. Brunner et al. Pharmacokinetics and Pharmacodynamics of Inhaled versus Subcutaneous Insulin in Subjects with Type 1 diabetes - A Glucose Clamp Study. ADA 2000
3. Knipes et al. Pharmacokinetics and Pharmacodynamics of pulmonary insulin delivered via the AERx DMS in type 1 diabetics. Diabetologia 2000;43(Suppl1) A202.
4. Balent et al. Dose-Response and system efficiency of pulmonary insulin in subjects with type 1 diabetes. EASD2000.
5. Brunner et al. Tr Eigenshaften Von inhalerbarem Löslichen Normalinsulin Bei Typ 1 Diabetekern. Annual Congress of the Austrian Diabetes Association 2000
6. Jendle J, Himmelmann A, Mellén A, Wollmer A, Petersen, Dahl. Pharmacokinetics and intra-subject variability of inhaled insulin in healthy smokers and non-smokers. ADA2001
7. Mellén, Himmelmann, Jendle et al. Pharmacokinetics of pulmonary insulin in healthy smokers and non-smokers. EASD2001. Diabetologia 2001;44(Suppl1) PS54.
8. Jendle J, Himmelmann A, Mellén A. Pharmakokinetik von inhalativem Insulin bei gesunden Rauchern und Nichtraucherern. Annual Congress of the Austrian Diabetes Association 2001.
9. Koenen C, Jendle J, Himmelmann A, Mellén A, et al. Pharmakokinetik von inhalativem Insulin (AERx iDMS) bei gesunden Rauchern und Nichtraucherern. Diabetes und Stoffwechsel 2003;12:71.
10. Jendle J and Norberg B. Insulin Detemir provides superior glycaemic control than insulin NPH or insulin glargine in type 1 diabetic subjects in a clinical setting. ADA2007. Diabetes Care 2007;56(Suppl 1) A548.
11. Adolfsson P, Örnham H and Jendle J. Continuous Glucose Monitoring and recreational SCUBA-diving. ADA2008. Diabetes Care 2008;57:A402.
12. Jendle J, Nauck MA, Matthews D, Frid A, Hermansen K, During M, Zdravkovic M, Strauss B. Liraglutide, a once-daily human GLP-1 analog, reduces fat percentage, visceral and subcutaneous adipose tissue and hepatic steatosis compared with glimepiride when added to metformin in subjects with type 2 Diabetes. ADA2008. Diabetes Care 2008;57:OR106.
13. Jendle J, Nauck MA, Matthews D, Frid A, Hermansen K, During M, Zdravkovic M, Strauss B, Garber A. The reduction in body weight with liraglutide, a once-daily human GLP-1 analogue for type 2 diabetes, primarily comes from fat tissue and the fat tissue lost is predominantly visceral fat. EASD2008. Diabetologia 2008;51(Suppl1) P797.
14. Khalili P, Jendle J et al. Adiponectin is an independent marker of glucose metabolism: A cross-sectional study in 4013 middle-aged men based on detailed oral glucose tolerance testing. EASD2008. Diabetologia 2008;51(Suppl1) P724.
15. Norberg B and Jendle J. Insulin Detemir Provides Sustained Improvement in the Glycaemic Control over a 4-Year Period in Type 1 Diabetic Subjects. EASD2008. Diabetologia 2008;51(Suppl1) P969.
16. Adolfsson P, Örnham H and Jendle J. Tissue glucose during scuba diving in diabetic and non-diabetic divers. EUBS2008.
17. Jendle J, Rittig S, Faerch M. A missense mutation in the AVPR2 gene causing severe congenital nephrogenic diabetes insipidus in both sexes and effectively treated with the combination indomethacin and hydrochlorothiazide. ICE2008. Endocrinologia & metabologia 2008;52:S929
18. Roberts GA, O'Neill C, Moore D, Abdelnour E, Lodge B, Wardrop B, Harrison M, Jendle J, Nauck MA, Frid A, Hermansen K, During M, Strauss BJ and Matthews DR. Liraglutide, a once-daily human GLP-1 analogue, reduces fat percentage, visceral and subcutaneous adipose tissue compared with glimepiride when added to metformin in subjects with type 2 diabetes. IES2008.
19. Adolfsson, Örnham och Jendle. Glukosvariationer hos dykare med och utan diabetes typ 1. Riksstämman 2008.
20. Matthews DR, Jendle J, Nauck MA et al. Liraglutide, a once daily human GLP-1 analogue, reduces fat percentage and visceral and subcutaneous adipose tissue compared with glimepiride when added to metformin in subjects with type 2 diabetes. DUK2009. Diabetic Medicine 2009;26:11.
21. Adolfsson P, Örnham H, Jendle J. Type 1 Diabetes and Recreational Diving - One controversial activity where continuous glucose monitoring could improve safety. ISPAD2009.
22. Ridderstråle M, Torffvit O, Lammert M, Nilsen B, Bøgelund M and Jendle J. Patient willingness-to-pay for liraglutide and exenatide in Sweden based on head-to-head clinical trial results. EASD2009. Diabetologia 2009; 52:(Suppl 91) S408.
23. Jendle J, Torffvit O, Ridderstråle M, Lammert M, Ericsson Å and Bøgelund M. Swedish patients with type 2 diabetes show willingness-to-pay for health improvements including weight loss, reduction in hypoglycaemia and glycaemic control. EASD2009. Diabetologia 2009;52:(Suppl1) S407.

24. Jendle J, Nauck MA, Matthews Dr, Frid A, Hermansen K, Zdravkovic, M, Strauss BJ, Garber A, Liebl A. Die reduction des körperrgewichtes mit liraglutide, einem humanen GLP-1 analogon zur einmal täglichen gabe bei typ 2 diabetes, basiert in erster linie auf dem abbau von fettgewebe hauptsächlich von viszeralem fett. Diabetol Stoffwechs 2009;4;P128. DOI: 10-1055/s-0029-122193324.
25. Jendle J. The risk of hypoglycaemia in subjects with diabetes mellitus-hinders for air cabin personnel. Riksstämman 2009.
26. Ridderstråle M, Torffvit O, Lammert M, Nilsen B, Bøgelund M and Jendle J. Patienters betalningsvilja för liraglutide och exenatid i Sverige baserat på resultat M från direkt jämförande studie. Riksstämman 2009.
27. Jendle J, Torffvit O, Ridderstråle M, Lammert M, Ericsson Å and Bøgelund M. Svenska patienter med typ 2 diabetes patients visar betalningsvilja för förbättrad hälsa inklusive viktörlust, minskat antal hypoglykemier och glykemisk kontroll. Riksstämman 2009.
28. Zinman B, Colagiuri S, Madsbad S, Bain, Jensen T, Falahati A, Jendle J. The Human GLP-1 Analog, Liraglutide, Improves BMI and Waist Circumference Since in Patients with Type 2 Diabetes: A Meta-analysis of Six Phase 3 Trials. ADA2010.
29. Jendle J, Torffvit O, Ridderstråle M, Ericsson Å, Lammert M, Nilsen B, Bøgelund M. Patient willingness-to-pay for liraglutide 1.2 mg and glimepiride based on head-to-head clinical trial results. ADA2010.
30. Meneghini L, Roberts A, de Vries H, Jendle J, Endahl L, Lyby K, Johansen T, Home P, Ratner R, Wendisch U, Birkeland K. SIBA, a New Generation, Ultra-long-Acting Insulin, in a Basal/bolus Regimen in Subjects with Type 1 Diabetes: Comparison to Insulin Glargine. ADA2010.
31. Norberg B, Jendle J. Insulin Detemir Provides Sustained Improvement in the Glycaemic Control in Type 1 Diabetic Subjects over a 5 Year Period. ADA2010.
32. Khalili P, Lundin F, Jendle J, Jungner I, Nilsson P. Increased pulse-pressure and systemic inflammation for risk prediction of cardiovascular disease during 40 years of follow-up in 96,000 subjects; the Värmland Health Study, Sweden. Accepted OP ESH2010.
33. B Zinman, S Colagiuri, S Madsbad, S Bain, T Jensen, A Falahati, J Jendle. The Human GLP-1 Analog, Liraglutide, Improves BMI and Waist Circumference in Patients with Type 2 Diabetes: A Meta-analysis of Six Phase 3 Trials. OP CDA2010.
34. P Khalili, F Lundin, J Jendle, I Jungner, PM Nilsson Sialic acid predicts incident cases of hospital-treated diabetes mellitus during 40 years of follow-up in a defined population: The Värmland Health Survey, Sweden. EASD2010. Diabetologia 2010;53:(Suppl1) S164.
35. L Meneghini, A Roberts, H de Vries, J Jendle, L Endahl, K Lyby, T Johansen, P Home, R Ratner, U Wendisch, and K Birkeland. SIBA; a new Generation ultra-long acting insulin, used in a meal-time+basal Regimen in people with type 1 diabetes: Comparison to Insulin Glargine. EASD2010. Diabetologia 2010;53:(Suppl1) S388.
36. Jendle J, Torffvit O, Ridderstråle M, Lammert M, Ericsson Å and Bøgelund M. Willingness-to-pay for diabetes drug therapy based on meta-analysis results. ISPOR2010. Value in Health 2010;13(7):A298.
37. J Jendle, L Meneghini, P Home, U Wendisch, R Ratner, T Johansen, L Endahl, K Lyby, A Roberts, H DeVries, K Birkeland. Insulin Degludec, en ny generation ultralångverkande insulin, vid basal-bolus regim hos personer med typ 1-diabetes: en jämförelse med insulin glargin. Riksstämman 2010.
38. J. Jendle, O. Torffvit, M. Ridderstråle, Å. Ericsson, B. Nilsen, M. Bøgelund Preferenser för olika aspekter av läkemedelsbehandling vid typ 2-diabetes baserat på resultaten av en meta-analys. Riksstämman 2010.
39. Jendle J, Zinman B, Colagiuri S, Madsbad S, Bain S, Jensen T, Falahati A. Liraglutid, en human GLP-1 analog, förbättrar BMI och midjemått hos personer med typ 2 diabetes: meta-analys av sex fas-3 studier. Riksstämman 2010.
40. Norberg B, Jendle J. Insulin detemir ger en bestående förbättring av den glykemiska kontrollen hos patienter med typ 1-diabetes över en 5-års period. Riksstämman 2010.
41. J Jendle. Lägre risk för hypoglykemi vid diabetes pga tekniska och farmakologiska landvinningar Riksstämman 2010.
42. P Home, L Meneghini, H DeVries, J Jendle, L Endahl, K Lyby, T Johansen, A Roberts, R Ratner, U Wendisch, K Birkeland. Insulin degludec in type 1 diabetes: comparison of a new-generation ultra-long-acting insulin vs insulin glargine in a meal-time+basal insulin regimen. DUK2010.
43. Lind M, Jendle J, Torffvit O, Lager I. Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with a low risk of hypoglycemia and high treatment satisfaction. ADA2011.
44. Home P, Meneghini L, Wendisch U, Ratner R, Johansen T, Christensen TE, Jendle J, Roberts A, DeVries H, Birkeland K. Better Quality of Life results (SF-36) for insulin degludec compared to insulin glargine in people with type 1 diabetes. EASD2011. Diabetologia. 2011;54(Suppl1) S384(941P).
45. J Jendle, P Adolfsson, H Örnhammar, R Shad, K Cooper, R Gautham. Glucose sensor performance during pressure changes. EASD2011. Diabetologia. 2011;54(Suppl1) S396(973P).
46. Örnhammar H, Adolfsson P and Jendle J. Swedish policy for diabetes and recreational diving. OP EUBS2011.
47. P Adolfsson, H Örnhammar, K Cooper, R Gautham, J Jendle. Good glucose sensor accuracy and less pain with insertion on the lower back. ISPAD2011.
48. Jendle J, Adolfsson P, Örnhammar H. Insulin treated diabetes mellitus and recreational SCUBA diving. IDF2011.
49. Adolfsson P, Örnhammar H, Raghavendhar G, Shaw R and Jendle J. In-vitro glucose sensor performance during hypobaric and hyperbaric conditions. ADTT2012.
50. Home P, Meneghini L, Ratner RE, Johansen T, Christensen TE, Jendle J, Roberts AP, DeVries JH and Birkeland KI. A comparison of quality of life measured with the SF-36 for insulin degludec and insulin glargine in people with type 1 diabetes. JDS2012. P349.
51. N. Freemantle, L. Meneghini, T. Christensen, M. Wolden, J. Jendle, R. Ratner. Health status in people with type 2 diabetes on basal-oral therapy is significantly improved with insulin degludec vs insulin glargine. ADA2012.
52. Jendle J, Freemantle N, Meneghini L, Christensen T, Wolden M, Ratner R. Health Status in People with Type 2 Diabetes on Basal-Oral Therapy is Significantly Improved with Insulin Degludec vs Insulin Glargine. EASD2012.
53. Freemantle N, Meneghini L, Christensen T, Wolden M, Jendle J. Health status in people with type 2 diabetes on basal-oral therapy is significantly improved with insulin degludec vs insulin glargine. CODY2012. 54. Roze S, Jendle J. Health economic benefits of continuous glucose monitoring versus self-monitoring of blood glucose in type 1 diabetes. ATTD2013. Diabetes Technology & Therapeutics 02/2013; 15:A65-A66.
55. M Yousef, A Westman, A Lindberg, C de Lacerda, J Jendle. Glucose changes in individuals with type 1 diabetes during air pressure changes as when skydiving. ATTD2013. Diabetes Technology & Therapeutics 02/2013; 15:A76-A77.
56. J Jendle, J Norlin, S Olofsson, P Lynch, N Halle, C Barsøe, S de Portu, U Persson. The value of a P-Cap

versus a Luer Lock insulin pump infusion set- a willingness to pay study in type 1 diabetes on insulin pump therapy. ATTD2013. *Diabetes Technology & Therapeutics* 02/2013; 15:A42-A42.

57. N Freemantle, L Meneghini, TE Christensen, M Wolden, J Jendle, RF Ratner. Health status in people with type 2 diabetes on basal-oral therapy is significantly improved with insulin degludec vs insulin glargin. JDS2013.

58. J Jendle, P Adolfsson, H Örnhammar. Need for international guidelines on diabetes mellitus and recreational SCUBA diving. Reunion2013.

59. J Jendle, L Blonde, J Rosenstock, V Woo, J Gross, H Jiang, Z Milicevic. Better glycaemic control and less weight gain with once weekly dulaglutide vs bedtime insulin glargine, both combined with thrice daily lispro, in type 2 diabetes (AWARD-4). EASD2014. *Diabetologia*, 2014;57(Suppl1) 42 OP.

60. J Gross, J Jendle, J Rosenstock, L Blonde, V Woo, H Jiang, Z Milicevic. Better Glycemic Control and Less Weight Gain with Once Weekly Dulaglutide versus Once Daily Insulin Glargine, Both Combined with Pre-Meal Insulin Lispro, in Type 2 Diabetes Patients (AWARD-4). CEBM2014

61. J Jendle, J Rosenstock, L Blonde, V Woo, H Jiang, J Gross, Z Milicevic. Better Glycemic Control and Less Weight Gain with Once Weekly Dulaglutide versus Once Daily Insulin Glargine, Both Combined with Pre-Meal Insulin Lispro, in Type 2 Diabetes Patients (AWARD-4). CDA2014.

62. P Adolfsson, J Jendle, H Örnhammar. In type 1 diabetes new technology creates opportunities to dive with increased safety. EUBS2014.

63. J Jendle, J Rosenstock, L Blonde, V Woo, J Gross, H Jiang, Z Milicevic. Better Glycemic Control and Less Weight Gain with Once Weekly Dulaglutide versus Once Daily Insulin Glargine, Both Combined with Pre-Meal Insulin Lispro, in Type 2 Diabetes Patients (AWARD-4). SGED2014.

64. J Jendle, L Blonde, V Woo, J Gross, H Jiang, Z Milicevic. Continuous Glucose Monitoring in Patients Treated with Once Weekly Dulaglutide or Glargine, both Combined with Prandial Insulin Lispro (AWARD-4 Trial Substudy). Oral presentation ADA2015.

65. LM Evans, M Ridderstråle, HH Jensen, M Bøgelund, MM Jensen, Å Ericsson, J Jendle. Quantifying the short-term impact of changes in HbA1c, weight and insulin regimen on health-related quality-of-life. ISPOR2015.

66. Jendle J, Ridderstråle M, Jensen H, Bøgelund M, Jensen M, Ericsson A, Evans M. Investigating the short-term impact of poor glycaemic control on the daily lives of people with type 2 diabetes. *J Value in Health*. 2015;18:A65. DOI:10.1016/j.jval.2015.03378.

67. J Jendle, M Testa, S Martin, H Jiang, Z Milicevic. Less glucose variability seen in Patients Treated with Once Weekly Dulaglutide or Glargine, both Combined with Prandial Insulin Lispro (AWARD-4 Trial CGM Substudy). OP EASD2015.

68. M Ridderstråle, LM Evans, HH Jensen, M Bøgelund, MM Jensen, Å Ericsson, J Jendle. Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health-related quality-of-life: a time-trade-off study. ISPOR2015.

69. P Adolfsson, S Mattsson, J Jendle. Accuracy of continuous glucose monitoring using different sensor sites during physical activity. OP ATTD2016.

70. S Roze, A Gherardi, S de Portu, J Jendle. Health-Economic analysis of the use of Sensor-Augmented Pump (SAP) therapy in Sweden compared to Insulin Pump Therapy alone (CSII), in type 1 diabetic patients. ISPOR2016.

71. J Jendle, A Delbaere, S de Portu, S Roze. Projection of health-economic benefits of sensor-augmented pump (640G and PLGM system) versus insulin pump therapy alone (CSII) in type 1 diabetes patients in Sweden. OP ADTT2017.

72. B Klinkenbijn, S Chaugule, C Graham, J Jendle. Evaluation of the long-term cost-effectiveness of G5 mobile continuous glucose monitoring (CGM) versus self-monitoring of blood glucose (SMBG) alone in type 1 diabetes from the Swedish societal perspective. ISPOR2017.

73. J Jendle, AL Birkenfeld, R Silver, K Uusinarkaus, L Højbjerg, HF Thomsen, M Davies. Effect of gastrointestinal adverse events on treatment satisfaction in semaglutide treatment of type 2 diabetes. ISPOR2017. *Value in Health*. doi.org/10.1016/j.jval.2017.08.481

74. A Sharif, J Jendle, KJ Källgren. Compliance to screening of diabetic retinopathy with 18- and 36-months interval. OP EASDec2018. *EJO* 2018;28(S1);9.

75. M Galavazi, S Jansson, J Jendle, J Karlsson. Long-term effects of low energy diet combined with CBT-based group treatment of patients with obesity on weight, quality of life and eating behaviour: a 2-year intervention study. IOB2018. *Obesity Facts* 2018;11 (Suppl. 1):284.21

76. S Edelman, J Jendle P Dandona, C Mathieu, D Tschöpe, F Thorén, M Scheerer, J Xu, AM Langkilde. Effect of adding dapagliflozin to as an adjunct to insulin in individuals with type 1 diabetes on urinary albumin excretion up to 52 weeks of treatment. ASN2018.

77. S Edelman, J Jendle, P Dandona, C Mathieu, FA Thorén, MF Scheerer, J Xu, AM Langkilde. Effect of adding Dapagliflozin as an adjunct to insulin urinary albumin to creatinine ratio over 52 weeks in adults with type 1 diabetes. WCIRDC2018.

78. GP Fadini, M Feher, T Krarup Hansen, HW de Valk, MM Koefoed, M Wolden, E Zimmermann, J Jendle. Reduced risk of any hypoglycaemia among patients with Type 1 diabetes switching to insulin degludec: a European, multi-national, multi-centre, prospective, observational study. (ReFLeCT). *Diabetic Medicine* 2019;36 (Suppl. 1);60 (Poster 81).

79. GP Fadini, M Feher, T Krarup Hansen, HW de Valk, MM Koefoed, M Wolden, E Zimmermann, J Jendle. Reduced risk of any hypoglycaemia among patients with Type 2 diabetes switching to insulin degludec: a European, multi-national, multi-centre, prospective, observational study (ReFLeCT). *Diabetic Medicine* 2019;36 (Suppl. 1);60 (Poster 82)

80. Jendle J, de Portu S, Roze S. Cost effectiveness analysis of MiniMed 670G system versus continuous subcutaneous insulin infusion, in individuals with type 1 diabetes. ATTD2019.

81. J Jendle, S Edelman, P Dandona, C Mathieu, FA Thoren, MF Scheerer, J Xu, AM Langkilde. Dapagliflozin as an adjunct to insulin on urinary albumin-to creatinine ratio over 52 weeks in adults with type 1 diabetes. ATTD2019.

82. HW de Valk, M Feher, T Krarup Hansen, J Jendle, A Merchante, MM Koefoed, EP Rizi, E Zimmermann, GP Fadini. Switching to insulin degludec from other basal insulins reduces rates of hypoglycemia across patient subgroups in routine clinical care: The ReFLeCT study. ADA2019.

83. HW de Valk, M Feher, T Krarup Hansen, J Jendle, A Merchante, MM Koefoed, EP Rizi, E Zimmermann, GP Fadini. Switching to insulin degludec from other basal insulins reduces rates of hypoglycemia (according to different definitions) in routine clinical care: The ReFLeCT study. ADA2019.

84. HW de Valk, M Feher, T Krarup Hansen, J Jendle, A Merchante, MM Koefoed, E Parvaresh Rizi, E Zimmermann, GP Fadini. Switching to insulin degludec from other basal insulins reduces rates of hypoglycaemia

	<p>across patient subgroups in routine clinical care: The ReFLeCT study. EASD2019.</p> <p>85. M Feher, HW de Valk, T Krarup Hansen, J Jendle, Å Merchante, MM Koefoed, E Parvaresh Rizi, E Zimmermann, GP Fadini. Reduced rates of hypoglycaemia irrespective of the definition used when switching to insulin degludec from other basal insulins in routine clinical care: The ReFLeCT study. EASD2019.</p> <p>86. J Jendle, M Thunander, S Sjöberg, B Ekman, A-C Mårdby, J D da Rocha Fernandes, J Gundgaard, Å Ericsson. Real-World Cost-Effectiveness of Insulin Degludec in Type 1 and Type 2 Diabetes Mellitus in a Swedish Setting after One Year. EASD2019.</p> <p>87. J Lahtela, S Edelman, J Jendle, P Dandona, C Mathieu, F Thorén, MF Scheerer, J Xu, AM Langkilde. On behalf of the DEPICT-1 and -2 Investigators. Effect of adding dapagliflozin as an adjunct to insulin on urinary albumin-to-creatinine ratio over 52 weeks in adults with type 1 diabetes. EASD2019.</p> <p>88. Jendle J, Thunander M, Ekman B, Sjöberg S, Ericsson Å, da Rocha Fernandes J, Mårdby AC, Malkin SJP, Hunt B. Switching to insulin degludec is a cost-saving therapy for patients with type 1 and type 2 diabetes in the Swedish setting based on real world data. PDB23, 2019-11, ISPOR Europe 2019, Copenhagen, Denmark</p> <p>89. Andersson E, Persson S, Hallén N, Ericsson Å, Thielke D, Lindgren P, Steen Carlsson K, Jendle J. Costs of diabetes complications in 2016: Hospital based care and production loss for 392,200 people with type 2 diabetes and matched controls. ADA2020.</p> <p>90. Catrina S, Hartvig NV, Kaas A, Møller JB, Mårdby A-C, Jendle J. Life with T1D: Real-world injection patterns of bolus and basal insulin. ADA2020.</p> <p>91. Jendle J, Hartvig NV, Kaas A, Møller JB, Mårdby A-C, Catrina S. Effect of late bolus injections on Time-in-Range studied by connected pens. ADA2020.</p> <p>92. de Valk HW, Feher M, Krarup Hansen T, Jendle J, Merchante A, Koefoed MM, Rizi EH, Zimmermann E, Fadini GP. Niedrigere Hypoglykämieraten nach verschiedenen Hypoglykämie-Definitionen bei Umstellung von anderen Basalinsulinen auf Insulin degludec im klinischen Alltag: die ReFLeCT Studie. Diabetes Kongress 2020.</p> <p>93. Hunt B, Ericsson Å, Gundgaard J, Møller JB, Valentine WJ, Jendle J. Evaluating the long-term cost-effectiveness of introducing a smart insulin pen in standard-of-care treatment of type 1 diabetes in Sweden. EASD2020.</p> <p>94. Catrina S-B, Hartvig NV, Kaas A, Møller JB, Mårdby A-C, Jendle J. Type 1 diabetes: real-world insulin injection patterns. EASD2020.</p> <p>95. Steen Carlsson K, Andersson E, Persson S, Hallén N, Ericsson Å, D Thielke, Lindgren P, Jendle J. Costs of diabetes complications - Hospital based care and production loss for 392,200 people with type 2 diabetes and matched controls in Sweden. OP EASD2020.</p> <p>96. HW de Valk, M Feher, T Krarup Hansen, J Jendle, MM Koefoed, E Parvaresh Rizi, E Zimmermann, GP Fadini. Switching to Degludec from Other Basal Insulins is Associated with Reduced Hypoglycaemia Irrespective of the Definition Used or Patient Characteristics. EASD2020.</p> <p>97. Cohen O, Holm AL, Buompiersiere MI, Jendle J. Cost-effectiveness analysis of the MiniMed™ 780G system versus multiple daily injections with intermittently scanned continuous glucose monitoring in individuals with type 1 diabetes in Sweden. Accepted ATTD2021.</p> <p>98. Jendle J, Eeg Olofsson K, Franzen S, Svensson AM, Levrat-Guillen F. Cost-Effectiveness of the FreeStyle Libre System versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Treatment not Reaching Glycemic Goals in Sweden. Accepted ADA2021.</p> <p>99. Persson S, Nilsson K, Karlsdotter K, Skogsberg J, Gustavsson S, Jendle J, Steen Carlsson K. Burden of established cardiovascular disease and type 2 diabetes: Hospital-based care, days absent from work, costs, and mortality. Accepted OP EASD2021.</p> <p>100. Sterner Isaksson S, Bensow Bacos M, Eliasson B, Thors Adolfsson E, Rawshani A, Lindblad U, Jendle J, Berglund A, Lind M, Axelsen M. Effects of nutrition education using a food-based approach, carbohydrate counting or routine care in type 1 diabetes: 12 months prospective randomized trial. Accepted OP DNSG2021.</p> <p>Patents: Diabetes device, a disposable ruler for 3-dimensional measurements of diabetic foot ulcers, Application 2006-Jul-25 Priority to PCT/SE2006/050273. Patent 2008-Jan-31. 2006-07-25 Publication of WO2008013485A1</p>
Jendle	<p>Performing Clinical Trials and Management and Health Care Administration, 1996, Gothenburg.</p> <p>GCP course, Brookwood Academy, London, 2000.</p> <p>GCP training, skill we care, 2009.</p> <p>Essentials in GCP, Brookwood academy, 2014.</p>
Courses	<p>Leadership, economy and administration. Nordic school of public health, Gothenburg 1998</p> <p>Future Leader, Kjer and Kjerulf, Module 1-4, Copenhagen, 2000-2001</p> <p>Mastering Statistical Issues in Drug Development, London, 2000</p> <p>Leadership development, AAA-leadership, Module 1-4, Skåne, 2003</p> <p>Advanced continuous subcutaneous insulinpump treatment, Stockholm 2005</p> <p>Advance clinical neuroendocrinology Gothenburg 2006</p> <p>SPSS, Karlstad, 2009</p> <p>Media training, JIC communications, UK, 2009</p> <p>Diving Medicine Courses; EDTC/ECHM curriculum, Bandos, Maldives, 2009</p> <p>Leadership training, FD Ledarskap, Frykenstrand, Värmland, 2009-2010</p> <p>Educational science for research supervisors, Karolinska Institutet, Stockholm, 2015</p> <p>Teaching in higher education, UP1 and UP2, Örebro University, 2014-2015</p> <p>EDTC training, step II, Gothenburg 2011, Gothenburg 2018</p> <p>Leadership development, Örebro University, 2018-2019</p>
Date & Signature:	June 2021